Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03354611 · ClinicalTrials.gov registry record · Phase 2
Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging
A Phase 2 study, sponsored by Koning Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03354611: Clinical Trial Phase 2 study, sponsored by Koning Corporation.
NCT03354611 is a Phase 2 study that was terminated before completion, run by Koning Corporation. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03354611, a Phase 2 study, was terminated before completion, sponsored by Koning Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
Up to one hundred (100) female patients will be enrolled and consented to participate in the study. These women will be enrolled from screening assigned BIRADS 0, patient complaint, or referral for second opinion. The enrolled patient will accept CE-CBBCT scans within 4 weeks of her diagnostic mammography and before breast biopsy if biopsy is needed. The final diagnostic workup outcome of these enrolled patients needs to include at least 30 confirmed cancers cases.
Primary Outcome
The existence of lesions in the breast
Interventions
- RADIATION Contrast Enhanced Cone Beam Breast CT Scan
- DRUG Contrast Dye, Iodinated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2021-09-01 |
| Phase | Phase 2 |
Why NCT03354611 stopped before completion
NCT03354611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Contrast Enhanced Cone Beam Breast CT Scan is the first listed.
NCT03354611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03354611 about?
NCT03354611 is a clinical study titled "Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging". Up to one hundred (100) female patients will be enrolled and consented to participate in the study. These women will be enrolled from screening assigned BIRADS 0, patient complaint, or referral for second opinion. The enrolled patient will accept CE-CBBCT scans within 4 weeks of her diagnostic mammo...
What is the current status of trial NCT03354611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2018-09-10. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT03354611?
The interventions under investigation include: Contrast Enhanced Cone Beam Breast CT Scan (RADIATION), Contrast Dye, Iodinated (DRUG).
Who is sponsoring clinical trial NCT03354611?
This trial is sponsored by Koning Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03354611's enrollment target sits among peer trials
21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI